تيڤاعديرم إسرائيل - العربية - Ministry of Health

تيڤاعديرم

teva pharmaceutical indust.ltd - diflucortolone valerate 0.1 %; isoconazole nitrate 1 % - cream - diflucortolone - for the local treatment of inflammatory skin conditions accompanied by secondary fungal infections.

ريپاݘلينيد تيڤع ١ ملغ إسرائيل - العربية - Ministry of Health

ريپاݘلينيد تيڤع ١ ملغ

teva pharmaceutical indust.ltd - repaglinide 1 mg - tablets - repaglinide - treatment of type ii diabetes.

نورميتن ١٠٠ إسرائيل - العربية - Ministry of Health

نورميتن ١٠٠

teva pharmaceutical indust.ltd - atenolol 100 mg - tablets - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

بيكالوتاميد تيڤع ٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

بيكالوتاميد تيڤع ١٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ١٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

أناستروزول تيڤع إسرائيل - العربية - Ministry of Health

أناستروزول تيڤع

teva pharmaceutical indust.ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

ليتروزول تيڤع إسرائيل - العربية - Ministry of Health

ليتروزول تيڤع

teva pharmaceutical indust.ltd - letrozole 2.5 mg - tablets - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.